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Introduction
Familial Mediterranean Fever (FMF) represents an auto-
inflammatory disease caused be MEFV gene mutation
characterized with attacks of polyserositis, commonly
seen among Turks, Arabs, Armenians and Jews. Therapy
with colchicine was proven to be effective in treatment of
FMF polyserositis and in prevention of amyloidosis devel-
opment. Colchicine resistant FMF is defined as 6 or more
attacks of polyserositis in a year, despite the regular and
sufficient usage of colchicine. The percentage of resistant
FMF has been reported as a 5-10% in the literature.
Although colchicine remains the gold standard for the
FMF treatment, anti-IL-1 drugs are used in the cases of
FMF resistant to colchicine therapy. Particularly carriers
of the M694V homozygous mutation prone to be resis-
tant to standard therapy and show a risk for development
of additional diseases.
Objective
In this case report, we are presenting a M694V homozy-
gous, colchicine resistant FMF patients with the diagno-
sis of inflammatory bowel disease, who developed
proteinuria, and who was consequently diagnosed with
focal segmental glomerulosclerosis (FSGS).
Case report
A two years old female patient, admitted to our hospital
with high fever and severe abdominal pain. She was com-
plaining of high fever (until 390 C) lasting for 3 days
accompanied with severe abdominal pain, being repeated
every week for the last 6 months. The patient was hospi-
talized at Gastroenterology department where she was
diagnosed as an inflammatory bowel disease and treated
with sulphasalazine and low dose prednisone. No clinical
response to the therapy was a reason for rheumatologic
consultation. Clinical findings of the patient and her
higher acute phase reactant levels are compatible with
FMF. Colchicine 1 mg/day was started with 1 mg/day.
MEFV gene analysis was revealed homozygote M694V
mutations. In spite of initial clinical improvement, attacks
of disease started to repeat so the patient was consider to
be a resistant to standard therapy so the therapy with
Anakinra 50mg/day was initiated. Because of partial clini-
cal response to Anakinra, canakinumab 5 mg/kg/dose
once in every two months was added. As a result, no dis-
ease attack was registered during the time period of one
with decreased acute phase reactants to normal value. In
further follow up of patient, disease attacks restarted so
the canakinumab dose interval was decreased to be given
once per month. Although the initial analysis of urine
was found to be normal, control urine tests revealed a
proteinuria and hematuria. The renal ultrasound exami-
nation was normal. Serological tests: ANA, Anti-ds-
DNA, C3, C4 levels were normal. Daily protein excretion
was measured as a 625 mg/day. Persisting proteinuria
and hematuria were a reason to perform a renal biopsy’s
which suspected amyloidosis. Pathological examination
showed mesengial cell proliferation and segmental sclero-
sis by PAS stain. Congo stain was negative for amyloido-
sis. Proteinuria together with mentioned pathological
findings was compatible for FSGS. Since the pulse pre-
dnisone therapy showed no clinical improvement, cyclos-
porine A was added in therapy. FMF attacks (fever,
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abdominal pain) restarted so the canakinumab dose was
increased to a 65 mg/day. Attacks were disappeared.
Conclusion
Amyloidosis and other renal pathological conditions
should be suspected in the case of proteinuria developed
at FMF patient being treated regularly with colchicine
and other treatment modalities. It is important to con-
sider a FSGS in differential diagnosis of FMF patients
with renal involvement.
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Authors’ details
1Istanbul University, Cerrahpasa Medical Faculty, Pediatric Rheumatology,
Istanbul, Turkey. 2Istanbul University, Cerrahpasa Medical Faculty, Pediatric
Nephrology, Istanbul, Turkey.
Published: 28 September 2015
doi:10.1186/1546-0096-13-S1-P95
Cite this article as: Barut et al.: Development of focal segmental
glomerulosclerosis in a patient with Familial Mediterranean Fever resistant
to colchicine therapy under treatment with Canakinumab. Pediatric
Rheumatology 2015 13(Suppl 1):P95.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Barut et al. Pediatric Rheumatology 2015, 13(Suppl 1):P95
http://www.ped-rheum.com/content/13/S1/P95
Page 2 of 2
